Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-7

  Adetifa, Ifedayo M O ^a   Ota, Martin O C ^a   Walther, Brigitte ^b   Hammond, Abdulrahman S ^a   Lugos, Moses D ^a   Jeffries, David J ^b   Donkor, Simon A ^a   Adegbola, Richard A ^a   Hill, Philip C ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b Medical Research Council United Kingdom Laboratories   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE ANTIGEN; TUBERCULOSTATIC AGENT; GAMMA INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MALE; MONITORING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULOSIS; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; TUBERCULOSIS; YOUNG ADULT;

EID: 77958593670     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012502     Document Type: Article

References (40)

1. WHO(2007) Tuberculosis. Fact Sheet No 104, http://wwwwhoint/mediacentre/factsheets/fs104/en/ Accessed April 10, 2007.
2. Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146: 340-354.
3. Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, et al. (2008) Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 3: e1379.
4. Dheda K, Smit RZ, Badri M, Pai M (2009) T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in highburden vs. low-burden settings. Curr Opin Pulm Med 15: 188-200.
5. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, et al. (2002) Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 40: 704-706.
6. Vordermeier HM, Chambers MA, Cockle PJ, Whelan AO, Simmons J, et al. (2002) Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun 70: 3026-3032.
7. Hill PC, Fox A, Jeffries D, Jackson-Sillah D, Lugos MD, et al. (2005) Quantitative T cell assay reflects the infectious load of Mycobacterium tuberculosis in an endemic case contact model. Clin Infect Dis 40: 273-278.
8. Adetifa IM, Brookes R, Lugos MD, de Jong BC, Antonio M, et al. (2007) Rising ELISPOT count prior to the onset of symptoms of full-blown tuberculosis disease. Int J Tuberc Lung Dis 11: 350-352.
9. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, et al. (2006) Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 193: 354-359.
10. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, et al. (2007) Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175: 282-287.
11. Nicol MP, Pienaar D, Wood K, Eley B, Wilkinson RJ, et al. (2005) Enzymelinked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. Clin Infect Dis 40: 1301-1308.
12. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, et al. (2004) Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38: 754-756.
13. Chee CB, Khinmar KW, Gan SH, Barkham TM, Koh CK, et al. (2009) Effect of TB treatment on T-cell interferon-{gamma} responses to M. tb-specific antigens. Eur Respir J.
14. Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah D, et al. (2006) Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 6: 66.
15. WHO (2009) Treatment of tuberculosis: guidelines. Geneva: World Health Organization WHO/HTM/TB/2009.420 WHO/HTM/TB/2009.420. 160 p.
16. Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, et al. (2003) Surveillance of drugresistant Mycobacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis 7: 390-393.
17. Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, et al. (2007) Comparison of Two Interferon Gamma Release Assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia. BMC Infect Dis 7: 122.
18. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, et al. (1997) Rapid effector function in CD8+ memory T cells. J Exp Med 186: 859-865.
19. Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, et al. (2006) Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. Int J Tuberc Lung Dis 10: 192-198.
20. Lugos MD, Adetifa IM, Donkor S, Hill PC, Adegbola RA, et al. (2009) Evaluation of the contribution of major T cell subsets to IFN-gamma production in TB infection by ELISPOT. Immunol Invest 38: 341-349.
21. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, et al. (2007) Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 8: 5.
22. Dheda K, Pooran A, Pai M, Miller RF, Lesley K, et al. (2007) Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (TSPOT. TB) and factors that may modulate test results. J Infect 55: 169-173.
23. Dominguez J, De Souza-Galvao M, Ruiz-Manzano J, Latorre I, Prat C, et al. (2009) T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn Microbiol Infect Dis 63: 43-51.
24. Bosshard V, Roux-Lombard P, Perneger T, Metzger M, Vivien R, et al. (2009) Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis? Respir Med 103: 30-34.
25. Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, et al. (2009) T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis 9: 23.
26. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, et al. (2009) In vivo and in vitro effects of antituberculosis treatment on mycobacterial Interferongamma T cell response. PLoS One 4: e5187.
27. Connell TG, Tebruegge M, Ritz N, Bryant PA, Leslie D, et al. (2010) Indeterminate interferon-gamma release assay results in children. Pediatr Infect Dis J 29: 285-286.
28. Herrmann JL, Belloy M, Porcher R, Simonney N, Aboutaam R, et al. (2009) Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS ONE 4: e4130.
29. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, et al. (2008) Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis 8: 11.
30. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, et al. (2009) Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 58: 197-204.
31. Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2: 251-262.
32. Klenerman P, Cerundolo V, Dunbar PR (2002) Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2: 263-272.
33. Kaech SM, Ahmed R (2001) Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2: 415-422.
34. Connell TG, Davies MA, Johannisen C, Wood K, Pienaar S, et al. (2010) Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children. BMC Infect Dis 10: 138.
35. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, et al. (2006) Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 1: 7.
36. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, et al. (2010) Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 24: 417-426.
37. Houben RM, Glynn JR, Mallard K, Sichali L, Malema S, et al. (2010) Human immunodeficiency virus increases the risk of tuberculosis due to recent reinfection in individuals with latent infection. Int J Tuberc Lung Dis 14: 909-915.
38. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, et al. (2006) Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 117: 1542-1548.
39. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, et al. (2004) Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 38: 966-973.
40. Adetifa IM, Ota MO, Jeffries DJ, Hammond A, Lugos MD, et al. (2010) Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis J 29: 439-443.